Latest news with #Neurosurgery
Zawya
12-06-2025
- Health
- Zawya
Aman Hospital first private hospital in Qatar to achieve neurosurgical milestone
Doha, Qatar. In Qatar's private healthcare sector, Aman Hospital has always set benchmarks and given a new leap of faith in healthcare innovation by being the first to use a 3D printed PEEK (Polyetheretherketone) implant in neurosurgery. This landmark procedure was conducted by Dr. Tarek Sunna, Head of Neurosurgery at Aman Hospital and is in line with the hospital's strive towards achieving excellence in medical care and continuing its tradition of patientfocused innovation and treatments. The complex surgery was made possible with the aid of advanced 3D imaging and printing technology which facilitated the custom fitting of a PEEK implant for the user. PEEK implants are the new gold standard for cranial reconstruction due to their superior biocompatibility, strength, and radiolucency. When compared to traditional materials of construction such as titanium or acrylic, PEEK implants are better, more durable, infection resistant and have reduced sensitivity to light and temperature. These factors ensure fewer complications in the long run making the PEEK material an ideal choice. Dr. Sunna, a highly regarded spine surgeon, recognized for his expertise in minimally invasive spine surgery (MISS). His reputation stems from his ability to perform complex spinal procedures with smaller incisions, reducing muscle damage, and a faster recovery time compared to traditional open surgeries. As the head of the surgical team, Dr. Sunna expressed: 'This is undoubtedly a wonderful step towards the advancement of neurosurgery and marks a transformative moment for neurosurgery in Qatar. The precision and adaptability of PEEK implants allow us to restore cranial defects with unprecedented accuracy, significantly improving recovery times and patient outcomes. At Aman Hospital, we are proud to bring such cuttingedge solutions to our patients, ensuring they receive world-class care right here in Qatar." As a premier healthcare destination, Aman Hospital continues to lead in specialized neurosurgery, orthopedics, and minimally invasive procedures. This achievement underscores its strategic investments in next-generation medical technology and its goal to not just meet global healthcare benchmarks but to exceed them and ensure patients in Qatar and the region have access to the most advanced treatments available anywhere in the world." For media inquiries or further information, please contact: Aman Hospital's Communications Department Aman Hospital, Qatar Email: info@
Yahoo
10-06-2025
- Business
- Yahoo
FG001 clinical data in High-Grade Glioma is now published in Neurosurgery
KØBENHAVN, DK / / June 10, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision cancer surgery, is pleased to announce its compelling phase I clinical data with FG001 has been published in Neurosurgery. The data is the first-in-human result of its proprietary near-infrared (NIR) optical imaging agent, FG001, in patients with malignant glioma undergoing surgery. The article, published in the prestigious journal Neurosurgery, which targets neurosurgeons, is entitled "Novel uPAR-targeting optical imaging agent ICG-Glu-Glu-AE105 (FG001) for visualization of malignant glioma during surgery: First-in-human study in 35 brain cancer patients" and identified with doi:10 1227/neu.0000000000003542, available here: link. "We are very pleased with the publication of the results from this first-in-human study that shows FG001 not only enables safe and targeted tumor identification including in the transition zone, being the tissue between the cancer and normal tissue which constitutesthe biggest challenge for the surgeon treating high-grade glioma - where the agent continued to produce visible fluorescence." said Morten Albrechtsen, CEO of FluoGuide; "FG001 has the potential to redefine how surgeons approach brain tumor resection" Next clinical step and regulatory pathFollowing the successful completion of this phase I study, FluoGuide is obtaining FDA regulatory advice prior to initiate the U.S. clinical trial supporting approval of FG001 guiding surgery of patients with High Grade Glioma. FluoGuide anticipates feedback from ongoing regulatory interactions over the summer. "I am pleased to see the first result of FG001 in patients with malignant glioma published" says Jane Skjøth-Rasmussen, MD, PhD, Chief Physician in the Department of Neurosurgery at Rigshospitalet, Copenhagen, Denmark and Principal Investigator of the trial and the author of the publication, and continues: "The data demonstrates FG001 to be well tolerated and shows a promise for guiding surgery of malignant glioma." In an editorial comment published together with the article Professor Pierre A. Robe, Chair of Neurosurgical Oncology at the University Medical Center (UMC) concludes: "Altogether, the results reported here are a welcome and exciting addition to the brain tumor neurosurgical community." Please refer to the published article for the full commentary. Glioblastoma is among the most aggressive and lethal forms of brain cancer, with a crucial need for tools that enable maximal tumor resection while preserving healthy brain tissue. FG001 lights up cancer, enabling surgeons to perform more precise surgeries. It is an novel imaging agent that targets the urokinase-type plasminogen activator receptor (uPAR), a protein highly expressed in tumor tissue but largely absent from normal brain cells. Key results from the phase I studyThe result is from the first clinical trial with FG001 in patients with High Grade Glioma and is an open-label, single-center phase I trial involving 35 patients, and FG001 was administered intravenously prior to brain surgery. A dose of 36 mg administered 12-19 hours before surgery provided optimal tumor visualization. The tumor-to-background fluorescence ratio (TBR) was relevant for all image system tested (>1.5) and up to 2.7 (TBR mean) and 3.6 (TBR max). Notably, FG001 achieved a sensitivity of 79% and a specificity of 100% in identifying malignant tissue confirmed by histopathology. Compared with the imaging agent 5-ALA, FG001 was observed to provide clearer delineation in deeper tissue layers due to its NIR fluorescence properties, with no observed false positives. FG001's safety profile was equally promising, with only few (4) mild drug-related adverse events linked to the drug. It was observed that unlike 5-ALA, no FG001-related nausea or vomiting was reported in patients receiving evening doses, underscoring FG001s favorable tolerability. High precision in the transition zoneThe transition zone, being the tissue between the tumor and the normal tissue, is of special attention to neurosurgeons as it is where they must make the difficult decisions between removing tissue that may be cancer and risking disabling patients by removing more brain tissue than necessary. FG001 worked well in the transition zone where all 7 samples were correctly classified by FG001 whereas 5-ALA had 2 false negative. When the efficacy was calculated for transition zone only, then specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV) were all 100% for FG001, whereas the numbers were 100%, 60%, 100%, and 50% for 5-ALA, respectively. For further information, please contact:Morten Albrechtsen, CEOFluoGuide A/SPhone: +45 24 25 62 66E-mail: ma@ Certified Adviser:Svensk Kapitalmarknadsgransking ABWebsite: About FluoGuideFluoGuide is a biotech company specializing in precision cancer surgery improving the outcome for cancer patients. The Company's lead product, FG001, a novel optical imaging agent that light up cancerous tissue to improve surgical precision in patients undergoing surgery. FluoGuide's products are expected to have a dual benefit - reducing both the frequency of local recurrence after surgery and reducing surgical complications. The improved precision will potentially increase the patients' chance of achieving a complete cure and lower healthcare costs. FG001 binds to the urokinase plasminogen activator receptor (uPAR) being extensively expressed by solid cancer. The photosensitizer therapy potential of FG001 could add a direct treatment effect of FG001 to further benefit for patients with cancer undergoing surgery. The Company has published strong results from phase II trials demonstrating the efficacy of FG001 in patients undergoing surgery to remove aggressive brain (high-grade glioma), head & neck (oral squamous cell carcinoma) and lung cancers (non-small cell lung cancer). FG001 has also been demonstrated very well tolerated across all patients. Based on this strong foundation, FluoGuide advances the development toward approval in aggressive brain cancer and head & neck cancer. FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker "FLUO". Read more about FluoGuide and upcoming events on AttachmentsFG001 clinical data in High-Grade Glioma is now published in Neurosurgery SOURCE: FluoGuide A/S View the original press release on ACCESS Newswire
CNN
05-06-2025
- Entertainment
- CNN
Morten Harket, lead singer of a-ha, has Parkinson's disease
Morten Harket has revealed he has Parkinson's disease. The singer of a-ha, the band behind the 1985 hit and innovatively animated music video 'Take On Me,' shared the news during an interview with the group's biographer. 'I've got no problem accepting the diagnosis,' Harket said. 'With time, I've taken to heart my 94-year-old father's attitude to the way the organism gradually surrenders: 'I use whatever works'.' Harket, 65, explained why he wanted to share his diagnosis publicly. 'Acknowledging the diagnosis wasn't a problem for me; it's my need for peace and quiet to work that has been stopping me. I'm trying the best I can to prevent my entire system from going into decline,' he said. 'It's a difficult balancing act between taking the medication and managing its side effects. There's so much to weigh up when you're emulating the masterful way the body handles every complex movement, or social matters and invitations, or day-to-day life in general.' According to Mayo Clinic, 'Parkinson's disease is a movement disorder of the nervous system that worsens over time.' Harket had 'advanced brain surgery' at the Mayo Clinic, which along with medication, 'have softened the impact of his symptoms,' the a-ha biographer, Jan Omdahl, wrote. 'In June 2024, Morten underwent a neurosurgical procedure in which electrodes were implanted deep inside the left side of his brain. These are connected to a small pacemaker-like device placed under the skin of the upper chest that sends electrical impulses through the electrodes into the brain,' Omdahl wrote. 'The method is called deep brain stimulation (DBS) and is among the most advanced treatments in neurology. The procedure had the desired effect: with the right electrical impulses now reaching Morten's brain, many of his physical symptoms practically vanished. In December 2024 he underwent a similar procedure on the right side of his brain, which was also successful.' Harket's voice, however, has been affected, he said. 'The problems with my voice are one of many grounds for uncertainty about my creative future,' Harket said.
Associated Press
05-06-2025
- Business
- Associated Press
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that Sandra Silberman, M.D., Ph.D., Chief Medical Officer of CNS Pharmaceuticals, will present at the Lenox Hill Hospital, Department of Neurosurgery's Brain Tumor Biotech Summit being held on June 5, 2025 in New York, NY. Details of the presentation are as follows: Title: The Future and Promise of TPI 287- A Brain Penetrating Taxane with Documented Evidence of Efficacy Against Glioblastoma Date and Time: Thursday, June 5, 2025 at 9:30 AM ET As part of the presentation Dr. Silberman will discuss the Company's drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) and docetaxel, in which it stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. While most taxanes are substrates for multi-drug resistant transporters, which maintain the blood brain barrier (BBB), TPI 287's clinical data suggest it has the potential to cross the BBB and treat CNS tumors. In a Phase 1 trial treating glioblastoma patients with TPI 287 in combination with bevacizumab (Avastin®), the efficacy data included 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients. TPI 287 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. The 2025 Brain Tumor Biotech Summit brings together innovators in neuroscience and oncology with investors in the field of biotechnology and healthcare life science. The Conference's goal is to foster and encourage collaboration among our neuroscience colleagues and the biotechnology community to accelerate the development of new, life-saving therapies for patients with brain tumors and other Central Nervous System diseases. For more information about the 2025 Brain Tumor Biotech Summit, please visit the event website. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients. For more information, please visit and connect with the Company on X, Facebook, and LinkedIn. Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. . These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. 'Risk Factors' in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ('SEC') and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. CONTACT: JTC Team, LLC Jenene Thomas 908.824.0775 [email protected] SOURCE: CNS Pharmaceuticals, Inc. press release
Yahoo
05-05-2025
- Business
- Yahoo
Why Integra LifeSciences (IART) Shares Are Getting Obliterated Today
Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 28.5% in the morning session after the company reported weak first-quarter 2025 results, which included a significant miss on full-year EPS guidance and the next quarter's revenue outlook. Segment results were mixed as key businesses like Neurosurgery and Tissue Technologies declined, pulled down by inventory issues and slower ordering patterns. Along with rising costs, margins and profit were dragged down as EBITDA and EPS both dropped, and cash flow was in the red. Even though management kept the full-year sales target, they had to cut their profit outlook due to tariff concerns. Overall, this quarter could have been better. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it's free. Integra LifeSciences's shares are very volatile and have had 21 moves greater than 5% over the last year. But moves this big are rare even for Integra LifeSciences and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was 2 months ago when the stock gained 13.6% on the news that the company reported strong fourth quarter 2024 results that beat analysts' EPS and EBITDA expectations. On the other hand, its full-year revenue and EPS guidance fell short of Wall Street's estimates. The company expects continued demand for its portfolio but flagged potential headwinds, including intermittent product shipping holds. Overall, while this was a strong quarter with solid execution, cautious guidance suggests near-term uncertainty. Integra LifeSciences is down 45.8% since the beginning of the year, and at $12.48 per share, it is trading 60.8% below its 52-week high of $31.86 from June 2024. Investors who bought $1,000 worth of Integra LifeSciences's shares 5 years ago would now be looking at an investment worth $240.51. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Sign in to access your portfolio
